Abstract | BACKGROUND: OBJECTIVES: SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, Issue 10), MEDLINE (1966 to November 2010) and EMBASE (1980 to November 2010) databases. In addition, we handsearched reference lists, conference proceedings of the International Society of Paediatric Oncology (SIOP) and American Society of Clinical Oncology (ASCO) meetings (1998 to 2010) and ongoing trials registers. SELECTION CRITERIA: DATA COLLECTION AND ANALYSIS: Two review authors independently performed the study selection, risk of bias assessment and data extraction including adverse effects. MAIN RESULTS: AUTHORS' CONCLUSIONS: No definitive conclusions can be made about the efficacy of cardioprotective agents for which pooling of results was impossible. Dexrazoxane prevents heart damage and no evidence for a difference in response rate or survival between the dexrazoxane and control groups was identified. The evidence available did not allow us to reach any definite conclusions about adverse effects. We conclude that if the risk of cardiac damage is expected to be high, it might be justified to use dexrazoxane in patients with cancer treated with anthracyclines. However, clinicians should weigh the cardioprotective effect of dexrazoxane against the possible risk of adverse effects for each individual patient.
|
Authors | Elvira C van Dalen, Huib N Caron, Heather O Dickinson, Leontien Cm Kremer |
Journal | The Cochrane database of systematic reviews
(Cochrane Database Syst Rev)
Issue 6
Pg. CD003917
(Jun 15 2011)
ISSN: 1469-493X [Electronic] England |
PMID | 21678342
(Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
|
Chemical References |
- Anthracyclines
- Antibiotics, Antineoplastic
- Cardiotonic Agents
- Razoxane
|
Topics |
- Anthracyclines
(adverse effects)
- Antibiotics, Antineoplastic
(adverse effects)
- Cardiotonic Agents
(therapeutic use)
- Cytoprotection
- Heart Diseases
(chemically induced, prevention & control)
- Humans
- Neoplasms
(drug therapy)
- Randomized Controlled Trials as Topic
- Razoxane
(therapeutic use)
|